Moreover, we found that the protein kinase inhibitor LX7101 reversed the aberrant phenotype of FMRP-deficient NPCs and neurons, and discuss putative molecular targets of LX7101 and its relationship to the pathological mechanism of FXS. This evidence concerns the gene FMR1 and fragile X syndrome.